Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2006-10-17
2006-10-17
Le, Long V. (Department: 1641)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007100, C435S007200, C436S063000, C436S086000, C436S089000, C436S173000, C436S178000, C436S501000, C436S518000, C530S300000, C530S350000, C530S387900
Reexamination Certificate
active
07122327
ABSTRACT:
The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of at least one disease state relative to recognition of the presence and/or the absence of the biopolymer, predict disease risk assessment, and develop therapeutic avenues against the disease.
REFERENCES:
patent: 5062935 (1991-11-01), Schlag et al.
patent: 6020208 (2000-02-01), Hutchens et al.
patent: 6033862 (2000-03-01), Matsuda et al.
patent: 0 770 875 (1997-05-01), None
patent: WO 90/14148 (1990-11-01), None
patent: WO 93/24834 (1993-12-01), None
patent: WO 98/07036 (1998-02-01), None
Finan et al. PNAS, vol. 98, No. 17, pp. 9889-9894, Aug. 14, 2001.
Galibert et al. Science, vol. 293, Issue 5530, pp. 668-672, 2001.
Wilson, R. Science, vol. 282, pp. 2012-2018, 1998.
Tockman et al. “Consideration in bringing a caner biomarker to clinincal application.” Cancer Research, Suppl. vol. 52, pp. 2711s-2718s, May 1992.
Hampel et al. “Core biological marker candidates of Alzheimer's disease -perspectives for diagnosis, prediction of outcome and reflection of biological activity.”Journal of Neural Transmission, 2004, vol. 111, pp. 247-272.
Takahashi et al., “Rapid and Sensitive Immunoassay for the Measurement of Serum S100β Using Isoform-specific Monoclonal Antibody”, Clinical Chemistry 45, No. 8, (1999) pp. 1307-1311.
Richter et al., “Composition of the peptide fraction in human blood plasma: database of circulating human peptides”, Journal of Chromatography B; 726 (1999) pp. 25-35.
Jungblut, et al., “Proteomics in human disease: Cancer, heart and infectious diseases”, Electrophoresis (1999) vol. 20, No. 10, pp. 2100-2110.
Kim, et al, “The reduction of NADH Ubiquinone oxidoreductase 24-and 75-kDa subunits in brains of patients with Down syndrome and Alzheimer's disease”, Life Sciences (2001) Vo. 68, No. 24, pp. 2741-2750.
Finan, et al., “The complete sequence of the 1,683-kb pSymB megaplasmid from the N2-fixing and endosymbiontSinorhizobium meliloti”, Proceedings of the National Academy of Sciences of the United States (2001) vol. 98, No. 17, pp. 9889-9894.
Database Swissprot 'Online! Retrieved from EBI (2000) accession No. Q9N3X8; XP-002232170.
Colwell, “Multifactorial Aspects of the Treatment of the Type II Diabetic Patient”, Clinical and Experimental (1997), vol. 46, No. 12, Supp 1, pp. 1-4.
Jackowski George
Marshall John
Cook Lisa V.
Le Long V.
McHale & Slavin P.A.
Nanogen Inc.
LandOfFree
Biopolymer markers indicative of type II diabetes does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Biopolymer markers indicative of type II diabetes, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Biopolymer markers indicative of type II diabetes will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3656828